Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Cellens
AddedFeb 18, 2024
UpdatedJun 18, 2026
Cellens

Cellens

Cellens: A Tufts University spinoff providing noninvasive cancer detection solutions since 2019.

HQ
Medford, MA, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

Cellens is a medical device company that provides clarity and focus on cancer detection.

Cellens is a Tufts University spinoff company dedicated to providing patients and doctors with clarity and confidence through noninvasive cancer screening. It was founded in 2019 and is based in Medford, Massachusetts.

Cellens - Similar Companies

Oncodea logo

Oncodea

oncodea.com

X-Zell logo

X-Zell

x-zell.com

CellMax Life logo

CellMax Life

cellmaxlife.com

Early Detection logo

Early Detection

cancer.us

GRAIL logo

GRAIL

grail.com

Thrive Earlier Detection logo

Thrive Earlier Detection

Freenome logo

Freenome

freenome.com

Exact Sciences logo

Exact Sciences

exactsciences.com

TellBio logo

TellBio

tellbio.com

Malcova logo

Malcova

Onko Solutions logo

Onko Solutions

Oncotect logo

Oncotect

oncotect.co

OncoHealth logo

OncoHealth

oncohealthcorp.com

The Blue Box Biomedical Solutions logo

The Blue Box Biomedical Solutions

thebluebox.ai

OncoCell MDx logo

OncoCell MDx

Cellens - Quick Facts

Who are Cellens' competitors?

Companies similar to Cellens include Oncodea, X-Zell, CellMax Life and Early Detection.

When was Cellens founded?

Cellens was founded in 2019.

Where is Cellens' headquarters located?

Cellens' headquarters is located in Medford, MA, US.

When was Cellens' last funding round?

Cellens' most recent funding round was for $585k (USD) in October 2022.

How much has Cellens raised to-date?

As of Oct 14, 2022, Cellens has raised a total of $585k (USD).

How many employees does Cellens have?

Cellens has 5 employees as of Feb 5, 2024.

Cellens - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
  • Machine Learning
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Detection
Tags
  • Data
  • Healthcare
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified